On Thursday, Shares of Eldorado Gold Corp (USA)(NYSE:EGO), subtract 1.70% and closed at $3.47 in the last trading session. The last trading range of the stock ranges between $3.34 and $3.52. Eldorado Gold Corporation will release its Q3 2016 Financial and Operational Results after the market closes on Thursday October 27, 2016. Paul Wright, President and Chief Executive Officer of the Company, will host a conference call on Friday October 28, 2016 at 8:30 am PT (11:30 AM ET). The call will be webcast and can be accessed at Eldorado Gold’s website.
Cabot Oil & Gas Corporation (NYSE:COG), dropped -0.66% and closed at $25.52 in the last trading session. The last trading range of the stock ranges between $25.51 and $25.93. The company’s Market capitalization is $12.10 Billion with the total Outstanding Shares of 465.15 million. Cabot Oil & Gas Corporation (COG) will host its third quarter 2016 earnings conference call on Friday, October 28, 2016 at 9:30 a.m. Eastern Time. The Company plans to issue its financial and operating results before the market opening on the same day.
Eli Lilly and Co (NYSE:LLY), lost -0.34% and closed at $81.47 in the last trading session. The last trading range of the stock ranges between $80.73 and $81.78. During the 52-week trading session the minimum price at which share price traded, registered at $67.88 and reached to max level of $88.16. Eli Lilly and Company (LLY) will present data from several studies which further reinforce the advancement of its diverse clinical cancer portfolio during the European Society of Medical Oncology’s (ESMO) 2016 Congress in Copenhagen, October 7-11. Presentations include new data on abemaciclib, a CDK 4 and CDK 6 inhibitor, and olaratumab, a PDGFRα blocking antibody that recently received a positive CHMP opinion, in addition to data on: pemetrexed, a multi-targeted antifolate; ramucirumab, a VEGF Receptor 2 antagonist; necitumumab, an EGFR blocking antibody; and prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor. Of these presentations, four are featured in late-breaking abstracts (two on abemaciclib, and one each on pemetrexed and ramucirumab).
The presentations on pemetrexed, ramucirumab and necitumumab include data from a few of Lilly’s immuno-oncology clinical collaborations with Merck (known as MSD outside the U.S. and Canada) in trials that are evaluating these molecules in combination with Merck’s pembrolizumab. Notably, the first results from KEYNOTE-021G – which studied pembrolizumab in combination with pemetrexed-plus-carboplatin contrast to pemetrexed-plus-carboplatin alone for the first-line treatment of patients with advanced nonsquamous non-small cell lung cancer regardless of PD-L1 expression – will be featured in the Presidential Symposium on October 9.